Promising cream for painful skin condition tested in tiny trial

NCT ID NCT04414514

Terminated Disease control Sponsor: Milton S. Hershey Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This small, early trial tested a cream called ruxolitinib 1.5% on 6 people with early-stage hidradenitis suppurativa, a painful skin condition that causes lumps and abscesses. The goal was to see if the cream could reduce inflammation and improve symptoms after 16 weeks. However, the study was terminated early, so we have very limited information about its effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ruxolitinib 1.5% cream
What this could lead to: If it works, this could point toward a topical treatment for early-stage hidradenitis suppurativa, reducing painful lumps and inflammation.
What could go wrong: This was a very small, early-phase trial that was terminated early, so results are limited. It is unclear if the cream will work for most people or have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIDRADENITIS SUPPURATIVA

Contacts and locations

Locations

Penn State Hershey Medical Center

Hershey, Pennsylvania, 17033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.